高危型人乳头瘤病毒DNA联合新柏液基细胞学检测初筛宫颈癌的价值
|
摘要
目的探讨高危型人乳头瘤病毒(HPV) DNA联合新柏氏液基细胞学(TCT)检测初筛宫颈癌的价值。方法选取2016年1月至2016年12月间河北省定州市人民医院收诊的893例妇女,取TCT采集的宫颈上皮脱落细胞,同时进行HPV-DNA检测。进行TCT检测结果与病理组织学结果比较,高危型HPV-DNA检测结果与病理组织学结果比较,TCT联合高危型HPV-DNA检查结果与病理组织学检测结果比较。结果 TCT检测结果与病理组织学结果阳性符合率为26. 3%,高危型HPV-DNA检测结果与病理组织学结果阳性符合率为37. 4%,TCT联合高危型HPV-DNA检测与病理组织学诊断阳性符合率为89. 2%。结论高危型HPV-DNA联合TCT检测对初筛宫颈癌有较高的诊断价值。
Objective To investigate the value of high risk human papillomavirus( HPV) DNA combined with new Thinprep liquid based cytology( TCT) in the detection of primary cervical cancer.Methods A total of 893 women who were treated at Dingzhou People's Hospital from January 2016 to December 2016 were selected as the subjects. The histopathological findings of cervical tissues were taken as the diagnostic criteria,and CIN I,CIN II,CIN III and invasive carcinoma were positive. TCT cervical epithelial cells were collected and a sample was detected by HPV-DNA. The results of TCT test,high risk HPV-DNA test,and combined TCT and HPV-DNA test were compared with pathological findings. Results The positive coincidence rate was 26. 3% between the results of TCT test and histopathological test. The positive coincidence rate was 37. 4% between high risk HPV-DNA test results and histopathological test results. The positive coincidence rate was 89. 2% between TCT and high-risk HPV-DNA combined detection and histopathological diagnosis. Conclusion High risk HPV-DNA combined with TCT has a high diagnostic value in screening cervical cancer.
Objective To investigate the value of high risk human papillomavirus( HPV) DNA combined with new Thinprep liquid based cytology( TCT) in the detection of primary cervical cancer.Methods A total of 893 women who were treated at Dingzhou People's Hospital from January 2016 to December 2016 were selected as the subjects. The histopathological findings of cervical tissues were taken as the diagnostic criteria,and CIN I,CIN II,CIN III and invasive carcinoma were positive. TCT cervical epithelial cells were collected and a sample was detected by HPV-DNA. The results of TCT test,high risk HPV-DNA test,and combined TCT and HPV-DNA test were compared with pathological findings. Results The positive coincidence rate was 26. 3% between the results of TCT test and histopathological test. The positive coincidence rate was 37. 4% between high risk HPV-DNA test results and histopathological test results. The positive coincidence rate was 89. 2% between TCT and high-risk HPV-DNA combined detection and histopathological diagnosis. Conclusion High risk HPV-DNA combined with TCT has a high diagnostic value in screening cervical cancer.
引文
[1] Wright TC,Stoler MH,Behrens CM,et al. Primary cervical cancer screening with human papillomavirus:end of study results from the ATHENA study using HPV as the first-line screening test[J]. Gynecol Oncol,2015,136:189-197.
[2]江丹,张娇珍,林秀慧,等.人乳头状瘤病毒检测在宫颈癌和宫颈癌前病变筛查中的应用[J].中国肿瘤临床与康复,2016,23:970-972.
[3]徐艺,杨静秀,王玉平. HC2-HPV检测法联合液基细胞学在宫颈癌及癌前病变筛查中的临床意义[J].实用癌症杂志,2016,31:1006-1008.
[4]方向东,赵卫东.二代杂交捕获技术联合液基细胞学检测在宫颈癌早期筛查中的临床应用[J].中国妇幼保健,2015,30:2672-2674.
[5] Syrj? nen K. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors[J]. Eur J Gynaecol Oncol,2008,29:205-221.
[6]王少云,谢东.宫颈液基薄层细胞学检测联合阴道镜在筛查宫颈癌前病变中的价值[J].中国性科学,2015,24:36-39.
[7]靳东芳,程金洛.膜式液基薄层细胞学检测联合高危型人乳头状瘤病毒分型检测在宫颈癌筛查中的应用[J].中国肿瘤临床与康复,2014,21:19-20.
[8]刘志红,邹艳芬.宫颈液基细胞学检查与高危型HPV检测早期筛查宫颈癌前病变的对比分析[J].现代肿瘤医学,2016,24:1269-1271.
[9]李玉霞,宋晓婕,陈莉,等.宫颈癌筛查中高危型HPV及液基细胞学联合应用的临床价值[J].中国妇幼保健,2015,30:479-481.
[10]樊岩岩,赵俭,左丽,等. HPV联合宫颈液基细胞筛查宫颈病变[J].中国卫生标准管理,2015,6:166-167.
[11]吴红,薛璇.阴道镜联合液基细胞学筛查宫颈病变的诊断价值[J].中国妇幼健康研究,2015,26:1275-1277.
[12]喻垚,郭变琴,罗光丽,等.液基细胞学与高危型HPV-DNA联合检测在宫颈病变筛查中的意义[J].检验医学与临床,2015,12:1550-1551.
[13]林雪珊,周全,何春妮.阴道镜和高危型HPV-DNA检测在宫颈不典型病变筛查中的应用[J].中华全科医学,2013,11:854-855.
[14]李沛,许云,杭国琴,等. TCT联合高危型HPV DNA检测在宫颈病变筛查中的诊断价值[J].国际检验医学杂志,2012,33:1123-1125.
[2]江丹,张娇珍,林秀慧,等.人乳头状瘤病毒检测在宫颈癌和宫颈癌前病变筛查中的应用[J].中国肿瘤临床与康复,2016,23:970-972.
[3]徐艺,杨静秀,王玉平. HC2-HPV检测法联合液基细胞学在宫颈癌及癌前病变筛查中的临床意义[J].实用癌症杂志,2016,31:1006-1008.
[4]方向东,赵卫东.二代杂交捕获技术联合液基细胞学检测在宫颈癌早期筛查中的临床应用[J].中国妇幼保健,2015,30:2672-2674.
[5] Syrj? nen K. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors[J]. Eur J Gynaecol Oncol,2008,29:205-221.
[6]王少云,谢东.宫颈液基薄层细胞学检测联合阴道镜在筛查宫颈癌前病变中的价值[J].中国性科学,2015,24:36-39.
[7]靳东芳,程金洛.膜式液基薄层细胞学检测联合高危型人乳头状瘤病毒分型检测在宫颈癌筛查中的应用[J].中国肿瘤临床与康复,2014,21:19-20.
[8]刘志红,邹艳芬.宫颈液基细胞学检查与高危型HPV检测早期筛查宫颈癌前病变的对比分析[J].现代肿瘤医学,2016,24:1269-1271.
[9]李玉霞,宋晓婕,陈莉,等.宫颈癌筛查中高危型HPV及液基细胞学联合应用的临床价值[J].中国妇幼保健,2015,30:479-481.
[10]樊岩岩,赵俭,左丽,等. HPV联合宫颈液基细胞筛查宫颈病变[J].中国卫生标准管理,2015,6:166-167.
[11]吴红,薛璇.阴道镜联合液基细胞学筛查宫颈病变的诊断价值[J].中国妇幼健康研究,2015,26:1275-1277.
[12]喻垚,郭变琴,罗光丽,等.液基细胞学与高危型HPV-DNA联合检测在宫颈病变筛查中的意义[J].检验医学与临床,2015,12:1550-1551.
[13]林雪珊,周全,何春妮.阴道镜和高危型HPV-DNA检测在宫颈不典型病变筛查中的应用[J].中华全科医学,2013,11:854-855.
[14]李沛,许云,杭国琴,等. TCT联合高危型HPV DNA检测在宫颈病变筛查中的诊断价值[J].国际检验医学杂志,2012,33:1123-1125.